Analytical Data
-
Gene name
IPO13
- Application
-
Alternative Names
IMP13; KAP13; RANBP13; Karyopherin-13; Ran-binding protein 13
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O94829
-
Expression Region
Gly14~Phe202
-
Molecular Weight
25kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IPO13 (Importin 13) is a member of the importin family, which plays a critical role in the nuclear transport of proteins and RNA molecules. It is particularly involved in the transport of larger proteins, including transcription factors and other nuclear proteins, across the nuclear envelope. Understanding the functionality and mechanisms of IPO13 is essential due to its implications in various biological processes, such as gene regulation, cell signaling, and the overall maintenance of cellular homeostasis. Dysregulation of nuclear transport can lead to several diseases, including cancer and neurodegenerative disorders. Recent studies have focused on characterizing the structural and functional aspects of IPO13, examining its interaction with cargo proteins and other importins, as well as its regulatory mechanisms. The exploration of IPO13 could provide insights into therapeutic targets for diseases associated with impaired nuclear transport. Additionally, the development of recombinant IPO13 proteins for further experimental applications could enhance our understanding of nucleocytoplasmic transport dynamics and their influence on cellular functions. Thus, IPO13 represents a vital area of research with potential implications in cell biology, disease mechanisms, and therapeutic innovations.
